Equities
Health CarePharmaceuticals & Biotechnology
  • Price (AUD)291.97
  • Today's Change-4.03 / -1.36%
  • Shares traded783.91k
  • 1 Year change13.71%
  • Beta0.4718
Data delayed at least 20 minutes, as of Oct 27 2020 05:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

  • Revenue in AUD (TTM)12.86bn
  • Net income in AUD2.96bn
  • Incorporated1991
  • Employees27.00k
  • Location
    CSL Ltd45 Poplar Road,, ParkvilleMELBOURNE 3052AustraliaAUS
  • Phone+61 39389-1911
  • Fax+61 39389-1434
  • Websitehttps://www.csl.com/
More ▼

Institutional shareholders

13.42%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202014.10m3.10%
The Vanguard Group, Inc.as of 30 Sep 202013.89m3.05%
Norges Bank Investment Managementas of 31 Dec 20195.47m1.20%
Vanguard Investments Australia Ltd.as of 30 Sep 20205.01m1.10%
BlackRock Investment Management (Australia) Ltd.as of 30 Jun 20204.63m1.02%
WCM Investment Management LLCas of 30 Sep 20204.15m0.91%
Capital Research & Management Co. (World Investors)as of 30 Sep 20203.99m0.88%
BlackRock Advisors (UK) Ltd.as of 30 Jun 20203.43m0.75%
BlackRock Investment Management (UK) Ltd.as of 30 Jun 20203.21m0.71%
Fidelity Management & Research Co. LLCas of 31 Aug 20203.19m0.70%
More ▼
Data from 31 Dec 2019 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.